Human Epididymis Protein 4 Predicted Concurrent Intermediate-high-risk Endometrial Cancer and Eligibility of Fertility-sparing Treatment for Patients Diagnosed with Endometrial Atypical Hyperplasia Before Surgery.

ABSTRACT: Objective: To investigate whether serum human epididymis protein 4 (HE4) could identify concurrent intermediate-high-risk endometrial cancer (EC) in patients diagnosed with endometrial atypical hyperplasia before definitive surgery (preoperative-EAH). Methods: This retrospective study analyzed preoperative-EAH patients who underwent hysterectomy at a tertiary hospital between January 2016 and December 2022. Results: Among 715 preoperative-EAH patients, 26.2% (187/715) were diagnosed with concurrent EC postoperatively, with 6.0% (43/715) identified as having concurrent intermediate-high-risk EC. Serum HE4 and postmenopausal status were revealed as independent predictors of concurrent EC. Receiver operator characteristic analyses determined optimal HE4 cut-off values of

SUBMITTER: Lou Y 

PROVIDER: S-EPMC12320788 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature